Illustration

Since April 1, 2008, the CDE HTA has been commissioned by 
the Ministry of Health and Welfare’s National Health
Insurance Administration to conduct HTA. The aim is to use
objective and evidence-based methodologies to assist in
decision-making for the reimbursement review meetings,
while also implementing the goals of the second-generation National Health Insurance and promoting diversified decision-making in medical technology assessment.

To assist manufacturers in planning or preparing submission
materials for new drug reimbursement under the National
Health Insurance, and to ensure the completeness of the new drug value statement and the reasonableness of budget
impact estimates, the CDE HTA has introduced the "HTA
Reimbursement Consultation Service." This service provides
consultation on these topics to manufacturers. The service
has been officially implemented since October 1, 2021.